PMID- 28294071
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
DP  - 2017 Mar 9
TI  - Safety of One-Week, First-Line, Standard Triple Therapy for Helicobacter Pylori 
      Eradication in a Japanese Population.
LID - 10.2174/1574886312666170310100209 [doi]
AB  - BACKGROUND: Standard triple therapy with the proton pump inhibitors, 
      clarithromycin and amoxicillin for Helicobacter pylori infection is considered to 
      be safe; however, the development of significant adverse events (AEs), such as 
      skin rashes, has been reported. OBJECTIVE: To reconfirm the safety of this 
      treatment. METHODS: This was a retrospective cohort study. After the exclusion of 
      patients allergic to penicillin, 322 consecutive patients, consisting of 305 
      outpatients and 17 inpatients, had received the first-line eradication treatment 
      with lansoprazole (30 mg), clarithromycin (200 mg), and amoxicillin (750 mg) 
      twice daily for 7 days. Their medical charts were reviewed, and data were 
      collected. RESULTS: Three patients discontinued the treatment because of the 
      development of a skin rash, mild diarrhea, and heat sensation, respectively. The 
      main AE observed was mild diarrhea in 50 patients. One patient had frequent 
      diarrhea, but it was readily resolved by a probiotic treatment. On the second or 
      third day after the conclusion of the treatment, a skin rash also occurred in six 
      patients (2%). Two of these patients and one patient who discontinued the 
      treatment were administered steroids as outpatients. They recovered within 1 
      month. CONCLUSION: Most AEs that developed were mild, except for some cases of a 
      rash. Rashes developed in spite of the exclusion of penicillin-allergic patients 
      and mainly after the completion of the one-week treatment. As a consequence of 
      little previous exposure to penicillin in the Japanese population, the 
      development of delayed rashes after this exclusion may represent first 
      sensitization to penicillin.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Hori, Kazutoshi
AU  - Hori K
AD  - Hyogo College of Medicine - Intestinal Inflammation Research Nishinomiya, Hyogo. 
      Japan.
FAU - Takagawa, Tetsuya
AU  - Takagawa T
AD  - Hyogo College of Medicine - Intestinal Inflammation Research Nishinomiya, Hyogo. 
      Japan.
FAU - Hida, Nobuyuki
AU  - Hida N
AD  - Hyogo College of Medicine - Intestinal Inflammation Research Nishinomiya, Hyogo. 
      Japan.
FAU - Nakamura, Shiro
AU  - Nakamura S
AD  - Hyogo College of Medicine - Intestinal Inflammation Research Nishinomiya, Hyogo. 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20170309
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - adverse event
OT  - amoxicillin
OT  - eradication treatment
OT  - eradication rate
OT  - penicillin
OT  - skin rash
OT  - standard triple therapy
EDAT- 2017/03/16 06:00
MHDA- 2017/03/16 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/09/04 00:00 [received]
PHST- 2017/01/15 00:00 [revised]
PHST- 2017/02/16 00:00 [accepted]
PHST- 2017/03/16 06:00 [entrez]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
AID - CDS-EPUB-82223 [pii]
AID - 10.2174/1574886312666170310100209 [doi]
PST - aheadofprint
SO  - Curr Drug Saf. 2017 Mar 9. doi: 10.2174/1574886312666170310100209.